Market

COFEPRIS Modernizes Mexico’s Federal Sanitary System
Management & Regulatory COFEPRIS Modernizes Mexico’s Federal Sanitary System

The rapid evolution of global pharmaceutical supply chains and medical technology necessitates a robust regulatory framework that balances safety with market speed. Under the leadership of Federal Commissioner Víctor Hugo Borja, the Federal Commission for Protection against Sanitary Risks, known as

Will Continuous Bioprocessing Transform Biomanufacturing?
Management & Regulatory Will Continuous Bioprocessing Transform Biomanufacturing?

Theglobalbiopharmaceuticalmanufacturinglandscapeiscurrentlyundergoingitsmostprofoundtransformationastheindustrymovesawayfromtheinefficienciesofbatchprocessingtowardaninterconnectedandfullyautomatedcontinuousproductionmodelthatenablestheconstantflowofmaterials. This shift marks the end of fragmented

FDA Briefing Casts Doubt on Capricor’s DMD Cell Therapy
Research & Development FDA Briefing Casts Doubt on Capricor’s DMD Cell Therapy

The pursuit of effective treatments for Duchenne muscular dystrophy has shifted focus toward managing cardiomyopathy, which currently stands as the most common cause of mortality for patients entering their second or third decade of life. Capricor Therapeutics recently faced significant headwinds

FDA Validates GTx-104 Clinical Data as Grace Eyes Approval
Management & Regulatory FDA Validates GTx-104 Clinical Data as Grace Eyes Approval

The critical window following an aneurysmal subarachnoid hemorrhage often determines the thin line between a successful recovery and permanent neurological deficit for thousands of patients every single year. These life-threatening brain bleeds require immediate and precise pharmacological

Can Pfizer’s GBS6 Navigate the Regulatory Gauntlet?
Research & Development Can Pfizer’s GBS6 Navigate the Regulatory Gauntlet?

Group B Streptococcus remains a formidable adversary in the realm of neonatal health, contributing to significant rates of sepsis, pneumonia, and meningitis in infants globally. Pfizer’s hexavalent Group B Streptococcus vaccine, known as GBS6, has recently reached a pivotal moment in its

Cultivated Meat Scale-Up Market to Hit $5.6 Billion by 2036
Biotech & Bioprocessing Cultivated Meat Scale-Up Market to Hit $5.6 Billion by 2036

The global food production landscape is currently undergoing a radical metamorphosis as cultivated meat moves from high-concept laboratory prototypes into the realm of multi-ton industrial manufacturing facilities. This transition signifies the emergence of a specialized infrastructure specifically

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later